Various names in the biotech sector are seeing big moves in today’s session, as investors are clearly interested in rotation into a number of higher-growth small-cap stocks. Immuneering (NASDAQ:IMRX) is certainly one such company generating outsized interest today. At the time of this writing, IMRX stock has surged more than 24% on news that the company was granted a fast track designation for its IMM-1-104 drug by the U.S. Food and Drug Administration (FDA).
This drug is aimed at patients suffering from pancreatic cancer and the fast track designation has reportedly been granted for patients suffering from both first- and second-line pancreatic ductal adenocarcinoma. The hope is that this designation will accelerate the company’s path to official approval of the drug, with a Phase 2a trial underway studying the impact of the treatment on pancreatic cancer, RAS-mutant melanoma and RAS-mutant lung cancer.
Let’s dive more into what Immuneering does and why IMRX stock is surging.
IMRX Stock Soars on Fast Track Designation from the FDA
Aside from an outright FDA approval for a particular drug, a fast track designation is one of the key catalysts many biotech investors like to see. Such designations allow prospective drugs to have an accelerated timeline for approval and typically rely on positive clinical trial data and strong efficacy arguments in order to be granted.
For investors in Immuneering, a clinical-stage oncology company focused on a range of cancers, this initial fast track designation is something many investors have clearly wanted. With a market capitalization of a little more than $40 million (after today’s rise), it’s clear this news improves the company’s prospective pathway to profitability moving forward. If this drug is officially approved at the end of the day for the range of cancer patients Immuneering is seeking to help, IMRX stock could have big-time upside worth considering.
Of course, there are plenty of risks to consider with such an investment as well. It’s unclear how long such a process will take (though the timeline has been greatly improved by this designation). Cash burn concerns and time to market are the key factors at play right now. That said, while uncertainty remains, this is a stock that has also moved up on the watch lists of many biotech investors today — and rightfully so. I’ll be watching IMRX stock closely and aim to provide additional updates as they come moving forward.
On Penny Stocks and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risks.
Read More: Penny Stocks — How to Profit Without Getting Scammed
On the date of publication, Chris MacDonald did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article.
